Amenorrhea secondary prevention

Revision as of 20:17, 5 October 2017 by Eiman (talk | contribs)
Jump to navigation Jump to search

Amenorrhea Microchapters

Home

Patient Information

Primary amenorrhea
Secondary amenorrhea

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Amenorrhea from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Amenorrhea secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Amenorrhea secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Amenorrhea secondary prevention

CDC on Amenorrhea secondary prevention

Amenorrhea secondary prevention in the news

Blogs on Amenorrhea secondary prevention

Directions to Hospitals Treating Amenorrhea

Risk calculators and risk factors for Amenorrhea secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

Effective measures for the secondary prevention of functional hypothalamic amenorrhea include oral contraceptive pills (OCPs), androgen therapy, recombinant insulin like growth factor 1 (IGF-1), recombinant leptin, bisphosphonates, and increasing calorie intake.

Secondary Prevention

  • Effective measures for the secondary prevention of functional hypothalamic amenorrhea include:

Oral contraceptive pills (OCPs)

  • Different studies have shown that OCP therapy can slow down the bone loss process in patients with exercise- and anorexia-associated amenorrhea. The detailed results are as following table:[1]
Treatment regimen Treatment duration Bone mineral density (BMD) site Outcome

Androgen therapy

  • It is assumed that 50, 100, or 200 mg of micronized DHEA daily can increase bone mineral density (BMD), and prevent the osteoporotic fracture. But there is not any established long term study to prove this effect.[2]

Recombinant insulin like growth factor 1 (IGF-1)

Recombinant leptin

Bisphosphonates

  • In adolescent women with anorexia-induced amenorrhea, alendronate (10 mg) with calcium (1200 mg) and vitamin D (400 IU) for a year show significant improvement in bone loss. Therefore, they can be used as secondary prevention.[5]
  • The major uses of bisphosphonates as secondary prevention for functional amenorrhea are as following table.

Increasing calorie intake

References

  1. Vescovi JD, Jamal SA, De Souza MJ (2008). "Strategies to reverse bone loss in women with functional hypothalamic amenorrhea: a systematic review of the literature". Osteoporos Int. 19 (4): 465–78. doi:10.1007/s00198-007-0518-6. PMID 18180975.
  2. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS (2002). "Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial". J. Clin. Endocrinol. Metab. 87 (11): 4935–41. doi:10.1210/jc.2002-020545. PMID 12414853.
  3. Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A (2002). "Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa". J. Clin. Endocrinol. Metab. 87 (6): 2883–91. doi:10.1210/jcem.87.6.8574. PMID 12050268.
  4. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS (2004). "Recombinant human leptin in women with hypothalamic amenorrhea". N. Engl. J. Med. 351 (10): 987–97. doi:10.1056/NEJMoa040388. PMID 15342807.
  5. Golden NH, Iglesias EA, Jacobson MS, Carey D, Meyer W, Schebendach J, Hertz S, Shenker IR (2005). "Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial". J. Clin. Endocrinol. Metab. 90 (6): 3179–85. doi:10.1210/jc.2004-1659. PMID 15784715.
  6. Viapiana O, Gatti D, Dalle Grave R, Todesco T, Rossini M, Braga V, Idolazzi L, Fracassi E, Adami S (2007). "Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight". Bone. 40 (4): 1073–7. doi:10.1016/j.bone.2006.11.015. PMID 17240212.
  7. Dominguez J, Goodman L, Sen Gupta S, Mayer L, Etu SF, Walsh BT, Wang J, Pierson R, Warren MP (2007). "Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses". Am. J. Clin. Nutr. 86 (1): 92–9. PMID 17616767.
  8. Fredericson M, Kent K (2005). "Normalization of bone density in a previously amenorrheic runner with osteoporosis". Med Sci Sports Exerc. 37 (9): 1481–6. PMID 16177598.

Template:WH Template:WS